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Retinoic acid treatment protects MRL/lpr lupus mice from the
development of glomerular disease.
Background. Retinoic acid (tRA) is an active metabolite of
vitamin A with potent anti-inflammatory properties. We ana-
lyzed the effects of tRA on the development of lupus nephritis
in MRL/lpr mice.
Methods. MRL/lpr mice received chow supplemented with
vehicle or tRA (daily 10 mg/kg) from 8 to 14 weeks until their
sacrifice. MRL/wt mice served as an additional control.
Results. tRA-treated MRL/lpr mice showed reduced lym-
phoadenopathy and splenomegaly as compared to vehicle-
treated controls. Treatment reduced proteinuria to almost basal
levels. Plasma IgG and anti-DNA antibodies increased compa-
rably in both vehicle and tRA-treated mice. Vehicle-treated
mice showed characteristic renal lesions. In contrast tRA-
treated mice showed almost normal glomerular histology with
a pronounced reduction in endocapillary cell proliferation.
T-cell and macrophage infiltrates were reduced after tRA
treatment within glomeruli and interstitium as compared to
vehicle-treated animals. In spite of this, immune complex and
complement deposition were comparable in both groups. Adop-
tively transferred T cells from vehicle-treated to tRA-treated
MRL/lpr mice did not induce renal lesions or proteinuria.
These beneficial effects of tRA treatment were associated with
reduced renal expression of chemokines and inflammatory
cytokines. Surprisingly, renal transforming growth factor-b
(TGF-b) mRNA levels of tRA-treated mice were elevated, pos-
sibly indicating that TGF-b acts as an anti-inflammatory signal
in this lupus model.
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Conclusion. tRA treatment reduces lymphoproliferation and
glomerulonephritis in MRL/lpr mice. This occurs in spite of un-
altered anti-DNA titers and glomerular immune complex depo-
sition, and cannot be overcome by T-cell transfer from nephritic
MRL/lpr mice.
Treatment with retinoic acid (tRA) derivates has been
reported to ameliorate renal disease in a variety of ex-
perimental models [1–9]. tRA is a natural active derivate
of vitamin A that regulates a broad range of biologic
processes through specific nuclear receptors [retinoic
acid receptors (RAR-a, RAR-b , and RAR-c or RXR-a,
RXR-b , and RXR-c)], which are structurally and func-
tionally related to glucocorticoid receptors [10]. tRA
is physiologically essential for embryonic development,
organogenesis, and organ functions [11,12]. Among other
actions, tRA has anti-inflammatory effects, reducing the
infiltration of leukocytes (mononuclear and polymor-
phonuclear cells) into sites of inflammation. Reduction
of the expression of monocyte chemoattractant protein-1
(CCL2/MCP-1) and other inflammatory cytokines by
tRA has been demonstrated both in vitro [13,14] and
in vivo [2, 6, 9]. It has been postulated that part of
the anti-inflammatory effect of tRA may be due to en-
hanced transforming growth factor-b (TGF-b) genera-
tion [15,16]. TGF-b is a multifactorial cytokine that has
major anti-inflammatory actions but also contributes to
chronic fibrosing precesses [17,18]. In addition, tRA is
a potent antiproliferative agent for different cell types,
including renal glomerular cells [19,20], promotes cell
differentiation [10], modulates extracellular matrix re-
modeling [1], and regulates apoptotic pathways in vitro
[10, 21]. Dietary deficiency of vitamin A has been re-
ported to affect innate and acquired immune response in
humans and rodents [22,23]. In vitro incubation of naive
Th0 cells with tRA leads to a Th2-type response by RAR-
mediated mechanism [22]. In vivo, tRA seems to regulate
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cellular immune response, since vitamin A deficiency
leads to a shift from a Th2-type to a Th1-type response
by increasing interferon-c (IFN-c) and interleukin (IL)-
12 mRNA synthesis while IL-4 and IL-5 production is
decreased [23]. These effects are reversed by supplemen-
tation with retinoids [23].
The anti-inflammatory and antiproliferative effects of
tRA have been examined in several types of kidney dis-
eases in animal models. In the rat model of Thy 1-1
mesangioproliferative glomerulonephritis tRA reduces
mesangial expansion, glomerular damage, and protein-
uria [2,3]. tRA also promoted the recovery of podocyte
function and structure and proteinuria in puromycin
aminonucleoside-induced nephrosis in the rat [4,5]. tRA
has also beneficial effects on tubulointerstitial damage
in a rat model of unilateral ureteral obstruction (UUO)
model, an effect which is associated with reduced expres-
sion of matrix components [8]. Finally, tRA significantly
ameliorated functional, vascular, glomerular, and tubu-
lointerstitial lesions in a rat model of acute renal graft
rejection [7]. Recently, Kinoshita et al [6] showed that
tRA treatment reduced autoimmune-mediated kidney
damage and increased survival of NZB/W F1 lupus mice.
The authors attributed this beneficial effect of tRA in this
mouse strain to decreased IFN-c and IL-2 expression and
a consequent shift of the immune response toward a Th2
phenotype.
In the present study we examined the effects of tRA
on the development of lupus-like renal disease in the
murine model of MRL/lpr mice. These animals carry a
mutation producing a nonfunctional fas protein, and, as
a consequence, apoptosis is almost completely abolished
[24,25], resulting in lymphoproliferation and the acceler-
ated development of autoimmunity [26]. The renal dis-
ease of MRL/lpr mice is initially characterized by the
glomerular deposition of immune complexes, binding and
activation of complement and the development of pro-
liferative glomerulonephritis [27, 28]. In the late course
of the disease terminal renal dysfunction leads to death
of the mice [28]. In a previous study we have demon-
strated the changes of different chemokines and proin-
flammatory cytokines in the development of the nephritis
in MRL/lpr mice [27].
In the present study we examined the effects of tRA
treatment on the development of nephritis in MRL/lpr
mice. Our results show that treatment with tRA has
protective effects on the lupus-like glomerular injury in
MRL/lpr mice and is associated with a reduction of re-
nal chemokine and cytokine expression. These effects
occur in spite of unaltered or even enhanced gener-
ation of autoantibodies and immune complex deposi-
tion within the glomeruli. As TGF-b mRNA levels are
elevated, we propose that TGF-b may contribute to
the tRA-induced suppression of the renal inflammatory
response.
Although tRA has some side effects, these are less se-
vere than those observed with classical steroid or other
immunosuppressive therapies. This fact makes tRA a
promising drug, which at present is mainly used in the
treatment of acute promyelocytic leukemia and other
neoplasic disorders [10] as well as in different inflamma-
tory skin diseases [29].
METHODS
Reagents and antibodies
The following antibodies were used: fluorescein isoth-
iocyanate (FITC)-conjugated rat antimouse IgG anti-
body (Dako, Glostrup, Denmark), FITC-conjugated goat
antimouse complement C3 IgG fraction (ICN, Aurora,
OH, USA) and peroxidase-conjugated goat antirabbit Ig
secondary antibody (Dako); rabbit antimouse Ki67 an-
tiserum (Dianova, Hamburg, Germany); rat antimouse
monocyte/macrophage monoclonal antibody (ER-HR3)
(Acris, Bad Nauheim, Germany) and rat antimouse CD3
antibody (Serotec, Oxford, UK). Kits were used for
the quantification of mouse albumin [enzyme-linked im-
munosorbent assay (ELISA) (Bethyl Laboratories, TX,
USA) and IgG [enzyme immunosorbent assay (EIA)
(BD Pharmingen, Dan Diego, CA, USA)].
All reagents for the anti-DNA ELISA were from
Boehringer Mannheim, except the mouse monoclonal
antisingle- and double-stranded DNA antibody used
as a standard (Chemicon International, Temecula, CA,
USA). Reagents for the detection of creatinine were
from Merck Diagnostika (Darmstadt, Germany). Radi-
olabeled [a-32P] uridine triphosphate (UTP) (3000 Ci/
mmol) for RNase Protection Assay was from NEN
(Boston, MA, USA). The multiprobe RNase protection
assay (RPA) template set mCK5 lacking the interferon-
producing protein-10 (IP-10) probe was from Pharmin-
gen (San Diego, CA, USA). tRA was from Sigma
Chemical Co. (St. Louis, MO, USA). All other reagents or
solvents (analysis grade) were from Merck (Darmstadt,
Germany).
Experimental protocol
MRL/MpJ-Tnfrsf6lpr (MRL/lpr) and MRL/MpJ-
Tnfrsf6+ (MRL/wt) mouse lines were obtained from
The Jackson Laboratory (Bar Harbor, ME, USA) and
bred and housed under specific pathogen-free conditions
and a 12-hour light and dark cycle, with free access to
water. The access to food was limited to achieve a nearly
complete intake. All experimental procedures were
performed according to German law after authorization
by local governmental authorities. At the age of 8 weeks,
virgin female animals were randomly distributed into
four different groups and fed with standard mouse auto-
cleavable chow (Sniff; Soest, Germany) supplemented
1020 Pe´rez de Lema et al: Retinoic acid in lupus nephritis
with tRA (10 mg/kg body weight) or control diet.
Supplemented chow pellets were prepared daily using a
1.68 mg/mL ethanolic tRA stock solution as previously
described [5], and the real intake was assessed by weigh-
ing the remaining food daily. Mice showing irregular
intake and those who took less than 80% of the mean
dose were rejected from further analysis. For each group,
8 to 12 mice were finally analyzed.
Blood and spot urine samples were obtained from each
mouse at week 8 (before the beginning of the treat-
ment), as well as at the end of the treatment as previously
described [27]. Albuminuria, antidouble-stranded DNA
antibodies, total circulating IgG levels were determined
using standard analytic protocols in accordance with pre-
viously described protocols [30].
After 6 weeks of treatment, mice were euthanized by
cervical dislocation. One kidney was used exclusively for
isolation of total RNA, using a standard protocol [31].
The other kidney was removed and split into two halves
and used for histologic and immunohistologic analysis.
The first half was fixed in 4% neutral buffered formalde-
hyde for 24 hours and then paraffin embedded. The other
half of the renal tissue was embedded in tissue freezing
medium (Jung; Leica Instruments, Wetzlar, Germany),
snap-frozen in liquid nitrogen, and stored at −80◦C until
used for immunohistochemical studies.
Light microscopy
Sections of 4 lm thickness from paraffin-embedded
renal tissue were routinely stained with hematoxylin
and eosin (H&E), periodic acid-Schiff (PAS), and sil-
ver methenamine stains. A renal pathologist blinded for
the treatment performed the histopathologic analysis as
previously described [27]. Glomerular lesions were semi-
quantitatively graded from 0 to 3+ for hypercellularity,
mesangial matrix expansion, and necrosis (0, absence;
1, mild; 2, moderate; and 3, severe), as well as for the
percentage of sclerotic glomeruli and presence of cres-
cents (0, less than 10%; 1, 10% to 25%; 2, 25% to 40%,
and 3, more than 40%). A glomerular score was ob-
tained from the sum of each parameter. Tubulointersti-
tial lesions were also graded from 0 to 3+ for peritubular
and pericapillar mononuclear cell infiltrate, tubular dam-
age, interstitial fibrosis and vasculitis. A tubulointersi-
tial score was also defined as the sum of all parameter.
Finally, perivascular lymphoproliferative mononuclear
cell infiltrate was graded from 0 (absence) to 3+ (maximal
intensity).
Immunohistochemistry
Studies were performed on paraffin-embeded sections
or cryosections and processed as described above, using
standard techniques [32].
Direct immunofluorescence studies were performed
on 5 lm, ether/ethanol-fixed, cryostat sections from three
independent mice by using FITC-conjugated rabbit an-
timouse IgG antibody and goat antimouse complement
C3 [30].
CD3, ER-HR3, and Ki67-positive cells were character-
ized and quantified on 4 lm thick paraffin sections from
renal tissue [30]. Peroxidase-conjugated goat antirabbit
or goat antirat IgG secondary antibody was always devel-
oped with diaminobenzidine as chromogen and counter-
stained with hemalaun. Respective isotype IgG control
served as negative controls. For quantification, positively
stained cells were counted within 20 glomeruli or within
10 high power fields (630×) of tubulointerstitial tissue
from four independent mice per group and expressed as
cells per glomerulus or high power field.
Renal mRNA expression
Chemokine expression was analyzed by a commer-
cial RPA as previously described [33]. Twenty micro-
grams of total RNA from each sample was used. The
RNase-protected probes were separated on 5% denatur-
ing polyacrylamide gels and analyzed by phosphorimag-
ing (Storm 840 PhosphorImager; Molecular Dynamics,
Sunnyvale, CA, USA). Bands were quantified using Im-
ageQuant software (Molecular Dynamics, Eugene, OR,
USA).
Adoptive T-cell transfer
T cells were isolated from the enlarged kidney-draining
lymph nodes of a proteinuric, 14 weeks old, untreated
MRL/lpr mouse. The lymph node was aseptically ex-
tracted and a cell dispersion generated in RPMI medium
supplemented with 10% fetal calf serum (FCS) and peni-
cillin/streptomycin (RPMI + 10% PS) by several gen-
tle strokes in a potter-homogenizer using a loose pestle.
After removing coarse debris by decantation, the remain-
ing cell suspension was collected, centrifuged for 5 min-
utes at 600g, washed in RPMI + 10% PS and cell number
determined using a Neubauer chamber. Two × 107 cells
were stained with PKH26 fluorescence dye according to
the manufacturer’s instructions (Sigma Chemical Co.).
After two washings, cells were resuspended in isotonic
saline to a final concentration of 1.5 × 107 cells/mL and
200 lL of the suspension were transferred by jugular vein
injection into age-matched MRL/lpr mice treated with
tRA for 6 weeks. Urine from these mice was collected
twice a week starting at day 8 before T-cell transfer until
their sacrifice 11 days after transfer. In addition to the
histopathologic analysis, cryosections of spleen, lymph
nodes, and kidneys were analyzed by fluorescence mi-
croscopy to assess the T-cell migration to these target
organs.
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Table 1. Effect of retinoic acid treatment (tRA) treatment on clinical
parameters in MRL/lpr mice
Vehicle tRA
Body weight g 36.6 ± 4.1 28.1 ± 1.3a
Lymph node weight mg 265 ± 109 125 ± 50a
Spleen weight mg 433 ± 48 248 ± 51a
White blood cell counts ×1000/lL 6.0 ± 1.2 6.9 ± 3.6
Values are mean ± SD of six to nine animals for each group at the age of 14
weeks.
aP < 0.05 vs. vehicle-treated animals.
Statistical analyses
Data were expressed as mean ± standard deviation
(SD) and analyzed for statistical significance with either
the unpaired two-way analysis of variance (ANOVA) and
t test with Bonferroni correction (for parametric data)
or the Kruskal-Wallis and Mann-Whitney U test (for
nonparametric data) as needed. The null hypothesis was
rejected at P < 0.05.
RESULTS
Body and organ weights
Treatment with tRA for 6 weeks resulted in a slightly
lower body weight as compared with vehicle-treated
MRL/lpr mice at 14 weeks of age (Table 1). This was
accompanied by visibly reduced lymphoadenopathy, as
well as a reduction in the spleen and lymph node weight.
Treatment had no effect on total peripheral white blood
cell counts (Table 1).
Biochemical parameters
Plasma IgG (Fig. 1A) and anti-DNA (Fig. 1B) anti-
body levels were determined at 8 and 14 weeks of age
from vehicle and tRA-treated MRL/lpr and MRL/wt
mice. MRL/lpr mice treated for 6 weeks from 8 weeks
of age with either vehicle (IgG 89.6 ± 57.6 mg/mL; anti-
DNA antibodies 2.1 ± 0.9 lg/mL) or tRA (IgG 155.8 ±
49.9 mg/mL; anti-DNA antibodies 2.79 ± 1.35 lg/mL)
showed comparably increased antibody concentrations
as compared to 8-week-old MRL/lpr mice (IgG 32.3 ±
27.4 mg/mL; anti-DNA antibodies 0.4 ± 0.3 lg/mL) or
14-week-old MRL/wt mice (IgG 36.1 ± 14.7 mg/mL; anti-
DNA antibodies 0,4 ± 0.1 lg/mL). No statistical differ-
ences in antibody levels between vehicle and tRA-treated
MRL/lpr mice were found (Fig. 1A and B)
As expected vehicle treated MRL/lpr mice developed
albuminuria at the age of 14 weeks (47.9 ± 33.7 lg al-
bumin/mg creatinine), as compared to either 8-week-old
MRL/lpr mice (0.9 ± 0.4 lg albumin/mg creatinine) or
14-week-old MRL/wt mice (0.6 ± 0.2 lg albumin/mg
creatinine). Development of proteinuria was almost
completely prevented by tRA treatment (3.1 ± 4.4 lg
albumin/mg creatinine), with urinary albumin excretion
close to basal levels (Fig. 1C).
Histopathologic and immunohistochemical findings
At the age of 8 weeks no histologic signs of renal lesions
were apparent in any of the groups. At week 14 of age,
vehicle-treated MRL/lpr mice showed well-established
renal alterations, mostly in glomerular but also in tubu-
lointerstitial compartments (Fig. 2C). Glomerular lesions
were characterized at this time point by enlarged, hyper-
cellular glomeruli with increased numbers of both resi-
dent cells and infiltrating leukocytes, as well as mesangial
matrix expansion (Fig. 2I). Interstitial lesions included
the presence of peritubular and pericapillar mononuclear
cell infiltrates, which were distributed focally and irreg-
ularly throughout the cortex of the affected kidneys. As
in human lupus, these interstitial lesions are very mild in
MRL/lpr mice at the age of 14 weeks. By contrast to the
mild interstitial lesions, the presence of large accumula-
tions of lymphoid cells located in the medulla and around
big renal vessels was noted in the 14-week-old MRL/lpr
mice. This is a hallmark of the lymphoproliferative state
of the MRL/lpr mice and does not represent real tubu-
lointerstitial inflammation.
After 6 weeks of treatment with tRA, 14-week-
old MRL/lpr mice showed reduced glomerular damage
(Fig. 2D), characterized by both reduced glomerular hy-
percellularity and mesangial matrix expansion as com-
pared to vehicle-treated animals (Fig. 2C). Glomerular
IgG immune complex and complement C3 deposition
were present to a comparable extent in both tRA-treated
and untreated mice (Fig. 2E to H).
As shown in Figure 2J, tRA treatment was as-
sociated with a dramatic reduction of endocapillary
cell proliferation as assessed by staining for the cell-
proliferation marker Ki67 (vehicle 2.97 ± 0.24 Ki67+
cells/glomerulus; tRA 0.13 ± 0.03; P < 0.05) and a re-
duction in the overall glomerular damage score (Fig. 2I).
In addition, tRA treatment markedly decreased the num-
ber of glomerular infiltrating T cells (vehicle 0.38 ±
0.06 CD3+ cells/glomerulus; tRA 0.13 ± 0.03; P <
0.05) and macrophages (vehicle 0.93 ± 0.12 ER-HR3+
cells/glomerulus; tRA 0.13 ± 0.04; P < 0.05) (Fig. 3). No
necrotic, sclerotic, or crescentic lesions were found.
The prominent perivascular lymphoproliferative le-
sions typical of MRL/lpr mice were not affected by
tRA treatment (not shown). However, in the cortical
tubulointerstitial compartment treatment with tRA did
markedly reduce the CD3+ lymphocytic (vehicle 9.0 ±
0.2 cells/high power field (630×); tRA 2.3 ± 0.2; P < 0.05)
and ER-HR3+ mononuclear cell infiltrate (vehicle 4.7 ±
0.7; tRA 1.6 ± 0.3; P < 0.05) (Fig. 3) present at 14 weeks
as compared to vehicle-treated MLR/lpr mice.
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Fig. 1. Effect of retinoic acid treatment
(tRA) treatment on biochemical findings in
MRL/wt and MRL/lpr mice. (A) Total plasma
IgG levels, detected by enzyme-linked im-
munosorbent assay (ELISA) and expressed
in mg/mL. IgG levels were significantly in-
creased in both 14-week-old vehicle- or tRA-
treated MRL/lpr mice as compared to 8-week-
old MRL/lpr mice or 14-week-old MRL/wt
mice (P < 0.05). The elevated IgG levels of
vehicle and tRA treatment groups were not
statistically different. (B) Total plasma anti-
DNA antibody levels, detected by ELISA and
expressed in lg/mL. Anti-DNA antibody lev-
els were significantly increased in both 14-
week-old vehicle- or tRA-treated MRL/lpr
mice as compared to 8-week-old MRL/lpr
mice or 14-week-old MRL/wt mice (P <
0.05). Anti-DNA antibodies in mice from ve-
hicle and tRA treatment groups were not
statistically different. (C) Albuminuria, de-
tected by ELISA, expressed as lg albumin
per mg urinary creatinine. At the age of 14
weeks, vehicle-treated animals showed signif-
icantly increased albuminuria as compared to
both 8-week-old MRL/lpr mice or 14-week-
old MRL/wt mice (P < 0.05). tRA treatment
reduced albuminuria to almost basal levels
(P < 0.05).
Renal mRNA expression of proinflammatory cytokines
and chemokines
Changes in the Th2/Th1 balance with changed expres-
sion of cytokines such as IL-12, IL-10, and IFN-c and
of chemokines is supposed to alter the course of exper-
imental lupus nephritis [27, 34–37]. We therefore ana-
lyzed the expression of proinflammatory cytokines and
chemokines in total kidney RNA by RPA (Fig. 4) and
compared them to vehicle-treated MRL/lpr mice (set at
100). In the tRA-treated animals, renal mRNA expres-
sion was reduced for IL-1a (16 ± 5 vs. 100 ± 46 in un-
treated MRL/lpr mice; P < 0.05), IL-1b (25 ± 12 vs. 100 ±
39; P < 0.05), INF-c–inducible factor (43 ± 13 vs. 100 ±
22; P < 0.05), and IL-12p35 (22 ± 9 vs. 100 ± 48; P <
0.05) as well as IL-12p40 (23 ± 12 vs. 100 ± 63, P < 0.05).
A nonstatistically significant reduction for IL-10 mRNA
(44 ± 18 vs. 100 ± 63) was also observed. No differences
in the mRNA levels of IL-1Ra and IFN-c were observed.
Treatment with tRA also significantly reduced the renal
expression of CCL5/RANTES (30 ± 7 vs. 100 ± 12 in
vehicle-treated mice; P < 0.05), CCL4/MIP-1b (45 ± 30
vs. 100 ± 11; P < 0.05), CCL3/MIP-1a (20 ± 9 vs. 100 ±
15; P < 0.01), and CCL2/MCP-1 (49 ± 14 vs. 100 ± 24;
P <0.05). CXCL1/MIP-2a showed the same tendency but
did not reach statistical significance (54 ± 31 vs. 100 ±
18). TGF-b is a multifunctional cytokine with impor-
tant roles in suppressing autoimmune reactions and in fi-
brosing processes [17,18]. We therefore also determined
renal TGF-b mRNA levels in vehicle and tRA-treated
MRL/lpr mice. Surprisingly, TGF-b mRNA levels in kid-
neys were somewhat elevated by tRA-treatment (179 ±
26 vs. 100 ± 14; P < 0.05).
Effect of adoptive T-cell transfer from untreated to
tRA-treated MRL/lpr mice
Our results with tRA treatment showed no effect on
one of the key events of immune-complex nephritis (i.e.,
the glomerular immune complex and complement depo-
sition), yet the glomerular disease was markedly atten-
uated. In order to analyze whether this might be due to
differences in T-cell activation we performed T-cell trans-
fer. T cells from renal lymph nodes from vehicle-treated,
nephritic and proteinuric mice (age 14 weeks) were trans-
ferred to tRA-treated mice (tRA + transfer) to see if this
could then trigger the nephritis. The transferred T cells,
which were fluorescently labeled with PKH26 dye prior
to transfer, could be detected within the lymph nodes and
the spleen, but not in the renal tissue of the tRA-treated
mice (not shown). As shown in Figure 5, tRA-treated
mice receiving 107 T cells from 14-week-old, vehicle-
treated MRL/lpr mice did not develop proteinuria
(Fig. 5C) or glomerulonephritis as judged by glomeru-
lar damage score (Fig. 5D) within 11 days post-transfer
(N = 7). Furthermore stopping the tRA treatment at the
day 0 did not result in the development of glomerular
disease or proteinuria during the next 11 days in the mice
previously treated with tRA and without T-cell transfer
(tRA + transfer) (Fig. 5A).
DISCUSSION
In the present work, we have studied the effects of
the administration of tRA on the development of re-
nal damage in MRL/lpr mice. As compared with ve-
hicle treatment, mice treated for 6 weeks with tRA
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Fig. 2. Effect of retinoic acid treatment (tRA) treatment on glomeru-
lar and tubulointerstitial damage in the MRL/lpr or MRL/wt mice.
Light microscopy (400×) showing periodic acid-Schiff (PAS)-stained
renal tissue from representative mice of the following experimental
groups: (A) vehicle-treated MRL/wt at 14 weeks of age, (B) 8-week-old
MRL/lpr, (C) 14-week-old vehicle-treated MRL/lpr, or (D) 14-week-
old tRA-treated MRL/lpr mouse. The prominent glomerular hypercelu-
larity and mesangial matrix expansion observed in 14-week-old vehicle-
treated MRL/lpr mice (C) is significantly prevented by 6 weeks of tRA
treatment (D). Fluorescence microcopy (100×) showing immunofluo-
rescence staining in vehicle-treated MRL/lpr mice for complement C3
(E) or for IgG (F) and in tRA-treated MRL/lpr for complement C3 (G)
or for IgG (H). (I) Semiquantitative analysis of glomerular damage in-
dex using the glomerular hypercellularity, mesangial matrix expansion,
and leukocyte exudate as injury parameters. The glomerular damage
index was significantly reduced in tRA-treated MRL/lpr mice as com-
pared to vehicle treated controls (P < 0.05). No statistical differences
were found between ML at 8 weeks of age or 14-week-old Mw and the
tRA-treated MRL/lpr mice. (J) Quantitative analysis of Ki67-positive
cells, counted in 50 glomeruli of kidney sections from four animals per
groups. The number of proliferating endocapillary cells was significantly
reduced in in tRA-treated MRL/lpr mice as compared to vehicle-treated
controls (P < 0.05). ML, MRL/lpr; Mw, MRL/wt.
showed, at the age of 14 weeks, (1) reduced lympho-
proliferation with smaller spleen and lymph nodes; (2)
failure to develop proteinuria and glomerular damage
with reduced endocapillar cell proliferation and reduced
lymphocyte and macrophage cell infiltrate, in spite of (3)
unchanged serum levels of IgG and AntiDNA antibodies
and unchanged glomerular immune complex deposition
and complement activation; (4) the reduced glomerular
injury by tRA was associated with reduced expression of
cytokines, except for TGF-b , which even increased; (5)
renal chemokine expression was reduced by tRA; and (6)
transfer of T cells from vehicle-treated mice did not cause
disease in tRA-treated mice.
At the beginning of treatment at the age of 8 weeks
no signs of palpable lymphoadenopathy, systemic au-
toimmunity, proteinuria or renal morphologic alterations
were evident. During the next 6 weeks vehicle-treated
mice developed splenomegaly and lymphoadenopathy,
which was markedly attenuated by treatment with tRA.
The mechanism by which MRL/lpr mice exacerbate au-
toantibody production is through the escape from fas-
mediated apoptosis of autoreactive lymphocytes [28].
A possible mechanism for reduced splenomegaly and
lymphoadenopathy in tRA-treated mice could be the
previously described increased, non-fas–dependent,
proapoptotic effect of tRA [38]. This explanation can-
not be ruled out, though we found no direct evidence
to support it. Spleens and lymph nodes of tRA-treated
mice showed histologically similar amounts of apoptotic
cells as vehicle-treated controls (data not shown). Most
likely tRA reduces general lymphoproliferation, perhaps
by causing maturation of lymphocytes in the primary lym-
phoid tissues. These effects would be similar to tRA ther-
apeutic effects in leukemia [10]. In any case, the multitude
of genes regulated by tRA does not allow assignment of a
single mechanism specific for the antiproliferative effects
observed.
Treatment with tRA prevented the development of
albuminuria and morphologic glomerular alterations so
that renal histology and function remained compara-
ble to 8-week-old MRL/lpr mice or 14-week-old, non-
nephritic MRL/wt mice. The reduction of glomerular
lesions by tRA included reduced hypercellularity, re-
duced mesangial matrix expansion, and reduced T-cell
and macrophage infiltration with concomitant absence
of proteinuria.
tRA has been described to successfully inhibit the de-
velopment of inflammatory renal disease in a rat model of
Thy 1-1 mesangioproliferative glomerulonephritis [2,3],
in puromycin aminonucleoside-induced nephrosis in the
rat [4,5] and recently in NZB/W F1 systemic lupus ery-
thematosus (SLE) mice [6], unilateral ureteral ligated rats
[8], and in a rat model of acute renal allograft rejection
[7]. In all these studies tRA treatment was associated
with decreased inflammatory cell infiltrate and, in gen-
eral, with decreased expression of proinflammatory cy-
tokines and growth factors. Our present observations of
reduced glomerular hypercellularity after tRA treatment
are in keeping with these reports. We could assign the
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9.03 ± 0.21Tubulointertitial
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2.28 ± 0.24* 4.67 ± 0.63 1.58 ± 0.33*
Fig. 3. Effect of retinoic acid treatment
(tRA) treatment on renal mononuclear cell
infiltration. Light microscopy (630×) showing
representative immunostaining for glomeru-
lar (A) and peritubular (C) CD3+ T cells
and for glomerular (B) and peritubular (D)
ER-HR3+ macrophages of representative re-
nal tissue from 14-week-old mice treated for
6 weeks with vehicle. As shown in Table 1
the quantitative analysis shows a significant
reduction in the glomerular and peritubular
CD3+ T cells and ER-HR3+ macrophages by
tRA as compared to vehicle-treated MRL/lpr
mice. For each mouse the mean of 20
glomeruli or 10 high power fields of intersti-
tial tissue (630×) were determined. The num-
bers express means ± SD of three animals per
group. ∗P < 0.05 vs. vehicle-treated animals.
reduced glomerular cellularity to a combination of de-
creased proliferation of glomerular cells, as assessed by
Ki67 staining, and reduced cell infiltration. The antipro-
liferative effect of tRA on renal and nonrenal cells is
supported by previous observations [19,20]. Wagner et al
described glomerular antiproliferative effects of tRA in a
rat model of mesangioproliferative nephritis [2,3]. A pos-
sible mechanistic explanation for the reduced glomeru-
lar cell proliferation could be that the reduced leukocyte
infiltration observed within the glomeruli of tRA-treated
mice may result in reduced glomerular production of me-
diators of inflammation and growth factors.
It is generally accepted that the generation of autoan-
tibodies and the subsequent glomerular deposition of im-
mune complex and complement activation is the major
trigger for the pathogenic process in lupus nephritis in hu-
mans [39] and in MRL/lpr mice [40,41]. Surprisingly, tRA
treatment neither reduced the levels of autoantibodies
nor altered the amount or the pattern of glomerular im-
mune complex and complement deposition. This argues
against the possibility of reduced immune complex depo-
sition and complement activation as an explanation for
the observed protective effect of tRA. Our observations
are somewhat discrepant from the recently reported de-
crease in immune complex deposition induced by tRA
treatment in the NZB/W F1 model of lupus nephritis
[6]. At present the reasons for this discrepancy remain
unclear but may relate to differences in the pathobiol-
ogy of the renal disease between both models [26, 42].
A number of reports do, however, support our observa-
tion that immune complex nephritis can be improved or
prevented in mice by experimental maneuvers in spite
of unaltered autoantibody production and immune com-
plex deposition. For example, uncoupling of the signal
transduction via Fcc receptors [43], or lack of inflamma-
tory cytokines or chemokines such as IFN-c [36], IL-12
[35], or CCL2/MCP-1 [37] reduces the glomerulonephri-
tis of lupus models in spite of unaltered glomerular im-
mune complex deposition. Based on these reports and
our results we conclude that in the case of the MRL/lpr lu-
pus nephritis autoantibody production, immune complex
and complement deposition is not sufficient to promote
leukocyte infiltration and the subsequent glomerular
inflammation.
As cytokines and chemokines play a role in immune
mediated glomerulonephritis [27] we examined their re-
nal expression as potential mechanisms for the benefi-
cial effects of tRA administration. Furthermore, reduced
expression of different cytokines such as tumor necrosis
factor-a (TNF-a), IL-1b , IFN-c, platelet-derived growth
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Fig. 4. Effect of retinoic acid treatment
(tRA) treatment on renal expression of cy-
tokines and chemokines in the MRL/lpr mice.
Expression of cytokines and chemokines in
kidney RNA from vehicle- and tRA-treated
mice at 14 weeks of age as assessed by
RNase protection assay (RPA). Values are ar-
bitrary units expressing the densitometric ra-
tio between a given gene and glyceraldehyde-
3-phophate dehydrogenase (GAPDH). The
mean of the vehicle-treatment group is set as
100. Results are means ± SD from three to
four mice per group. ∗P < 0.05 vs. vehicle-
treated mice.
factor (PDGF), or CCL2/MCP-1 was noted after tRA
treatment in models of anti-glomerular basement mem-
brane (GBM) [9], puromycin [5] or lupus nephritis [6].
Our present observations of reduced cytokine expression
are in keeping with those observations. Of special interest
are the reduced mRNA levels for IL-12 that we observed.
It has been previously described that IL-12 expression
is reduced by tRA in macrophages [14]. In the model
of pristan-induced lupus nephritis mice deficient for IL-
12p35 showed no signs of proliferative glomerulonephri-
tis or proteinuria [35] in spite of unchanged levels of
nephritogenic autoantibodies, immune complex deposits
and complement activation. Similarly, in MRL/lpr mice
deficient for IL12p40 the glomerular pathology was im-
proved while peripheral antibody levels were unchanged
and only a slight reduction of immune complex deposi-
tion has been reported [44]. In our present results the
renal expression of IL-12p35 and IL-12p40 was reduced
by 80% by tRA treatment in MRL/lpr mice. The down-
regulation of IL-12 by tRA could help to explain why the
renal disease was reduced by tRA in spite of the elevated
serum levels of IgG and anti-DNA antibodies and im-
mune complex deposition. Furthermore IL-12 can drive
the expression of IFN-c [45], another cytokine which ap-
pears to play a key role in the development of glomeru-
lonephritis in NZB/W F1 [46] and MRL/lpr mice [36, 47].
While tRA has been reported to inhibit the expression
of IFN-c in NZB/W F1 mice [6], in our model the re-
nal expression of IFN-c was not altered by tRA. Thus,
a change in IFN-c appears an unlikely contributing fac-
tor for the beneficial effect of tRA treatment in MRL/lpr
nephritis. On the other hand, the reduction of the proin-
flammatory cytokines IL-1a, IL-1b , and TNF-a together
with the suppression of IL-12 could contribute to the re-
duced renal inflammation in MRL/lpr mice treated with
tRA [27]. Suppressed IL-1 and IL-12 expression, together
with the unreduced peripheral IgG titers, point toward a
possible shift of the immune response to a predominant
Th2 phenotype as a possible mechanism contributing to
the reduced renal inflammatory response.
In a previous study, we have shown that several
chemokines are up-regulated early during the develop-
ment of nephritis in MRL/lpr mice [27]. The significance
of CCL2/MCP-1 expression was evaluated by Tesch et al
[37] in CCL2/MCP-1–deficient MRL/lpr mice. The lack
of CCL2/MCP-1 markedly decreased macrophage and
T-cell infiltration, glomerular damage, proteinuria, and
prolonged survival as compared with wild-type litter-
mates in spite of unchanged circulating immune complex
levels and glomerular deposition of immune complex
[37]. Furthermore a CCL2/MCP-1 antagonist also im-
proves the renal disease of MRL/lpr mice [48]. Our
finding that tRA administration also reduces renal
chemokine expression, including CCL2/MCP-1, is there-
fore of interest. This reduction in local chemokine gener-
ation could help to explain the decreased number of in-
filtrating T cells and macrophages that we observed after
tRA administration. It is unlikely that reduced expres-
sion of chemokine receptors on the surface of leukocyte
contributes to this effect as we found no changes in the
CCR2 and CCR5 surface expression on peripheral blood
leukocytes by flow cytometric analysis from tRA treated
MRL/lpr mice as compared to vehicle-treated controls
(data not shown).
Immune complex deposition and complement C3 are
both factors, which induce glomerular chemokine synthe-
sis [49]. Since tRA reduces the expression of chemokines
and cytokines in spite of unaltered immune complex
deposition and complement activation, the question is,
how could tRA treatment suppress chemokine pro-
duction in kidneys of MRL/lpr mice? A hypothetical
factor could be the enhanced generation of TGF-b in
response to tRA, which could reduce renal cytokine
and chemokine expression. TGF-b is a multifactorial
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Fig. 5. Effect of adoptive T-cell transfer from untreated to retinoic
acid treatment (tRA)-treated MRL/lpr mice on glomerular pathology
and proteinuria. Light microscopy (400×) showing periodic acid-Schiff
(PAS)-stained renal tissue from representative mice from tRA-treated
mouse 11 days after receiving 107 T cells from 14-week-old proteinuric
vehicle-treated mouse (A) or from tRA-treated mouse without T-cell
transfer (B). No difference is apparent. Adoptive T-cell transfer had
no effect on the development of either renal damage as evaluated by
the glomerular score (C) or albuminuria (D). The glomerular injury
score was determined at day 11 after transfer except for the vehicle
group, where the evaluation was performed on the day of transfer. Al-
buminuria was determined twice a week starting 8 days before transfer
(day 0) until sacrifice at day 11 post-transfer. No increase in proteinuria
was observed in tRA-treated mice, irrespective of whether they were
transferred (tRA + transfer) or not (tRA transfer). Albuminuria and
glomerular score values are means ± SD of five to ten mice per group.
cytokine which exerts, depending on the overall condi-
tions, either beneficial effects during inflammation, by
acting as an anti-inflammatory, proapoptotic, and an-
tiproliferative cytokine, or detrimental effects, by act-
ing as a profibrotic cytokine [17,18]. In this context, it
is of special interest that genetic disruption of the TGF-
b gene results in the development of severe autoimmu-
nity [50,51], whereas TGF-b overexpression can improve
Th1-mediated inflammation, inhibit collagen synthesis,
and reduce pulmonary fibrosis in an IL-10 dependent
manner [52]. Finally, TGF-b is directly able to reduce
chemokine production in cultured glomerular mesangial
cells [53]. The increase in renal mRNA expression of
TGF-b that we observed after tRA treatment could point
toward a positive effect of TGF-b on the autoimmune dis-
ease of MRL/lpr mice, possibly by a direct effect of tRA
on TGF-b generation as reported by Glick et al [15,16].
Thus induction of TGF-b by tRA in MRL/lpr lupus
nephritis could reduce the expression of proinflammatory
cytokines and chemokines and thereby improve the renal
disease process in spite of unaltered glomerular immune
complex and complement deposition. This hypothesis
could be considered to be in conflict with the observations
that tRA down-regulate the expression of TGFb in anti-
Thy 1-1- [1] and anti-GBM glomerulonephritis [9] and in
unilateral ureter ligation in the rat [8]. These apparent
discrepancies might relate to the different pathogenic
mechanisms between the above models and the au-
toimmune SLE-like disease of MRL/lpr mice. Beneficial
effects of TGF-b in an autoimmune setting are well sup-
ported by the literature [15,16, 50,51]. On the other hand,
detrimental effects of TGF-b in chronic fibrotic disease
are equally well documented [1, 8,9], illustrating the two
sides of TGF-b in disease process [18]. Support for such
dual effects of TGF-b comes from a recent report on dif-
ferent outcomes with different degrees of TGF-b block-
ade in puromycin nephrosis [54]. The hypothesis of ben-
eficial effects of TGF-b as an anti-inflammatory cytokine
in autoimmune glomerulonephritis has to be further an-
alyzed in the future.
The discrepancy between the unaltered antibody levels
and glomerular deposition of immune complex on the one
hand and the lack of glomerular cell infitration and pro-
liferation on the other hand led us to consider that tRA
treatment had altered the phenotype of the lymphocytes.
We therefore performed adoptive T-cell transfer from
nephritic, proteinuric, vehicle-treated 14-week-old mice
into age-matched tRA-treated mice. If the tRA treatment
had altered the phenotype of T cells the passive transfer
could have resulted in glomerular inflammation. In prin-
ciple, with this type of experiments effects mediated by
T cells can be transferred as shown, for example, for anti-
GBM nephritis [55]. However, the transfer experiments
did not support the notion of tRA-mediated alteration of
T-cell phenotype as a key feature for the glomerular pro-
tection. This leaves us with the notion of a locally altered
inflammatory milieu contributing to the beneficial effects
of tRA treatment in MRL/lpr mice. Such a beneficial ef-
fect could also involve decreased infiltration of activated
T cells because of reduced chemokine generation.
Taken together, our results suggest that tRA treat-
ment protects MRL/lpr from the development of immune
complex–mediated glomerulonephritis by influencing
the expression patterns of mediators of inflammation.
The beneficial effect may relate to the coordinated
down-modulation of chemokines such as CCL2/MCP-1,
CCL3/MIP-1a, CCL4/MIP-1b , and CCL5/RANTES
and of the proinflammatory cytokines IL-1a, IL-1b ,
leukotriene b , IL-12, or TNF-a. As retinoids are already
in use for oncologic and dermatologic diseases, its poten-
tial therapeutic value in SLE should be evaluated.
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